Enantiomerically Pure Thrombin Inhibitors for Exploring the Molecular-Recognition Features of the Oxyanion Hole

A new route via intermediate pseudoenantiomers was developed to synthesize racemic and enantiomerically pure new non-peptidic inhibitors of thrombin, a key serine protease in the blood-coagulation cascade. These ligands feature a conformationally rigid tricyclic core and are decorated with substituents to fill the major binding pockets (distal (D), proximal (P), selectivity (S1), and oxyanion hole) at the thrombin active site (Fig. 1). The key step in the preparation of the new inhibitors is the 1,3-dipolar cycloaddition between an optically active azomethine ylide, prepared in situ from L-(4R)-hydroxyproline and 4-bromobenzaldehyde, and N-piperonylmaleimide (Scheme 1). According to this protocol, tricyclic imide (compounds (±)-15-(±)-18 and (+)-21) and lactam (compound (+)-2) inhibitors with OH or ether substituents at C(7) in the proline-derived pyrrolidine ring were synthesized to specifically explore the binding features of the oxyanion hole (Schemes 2–4). Biological assays (Table) showed that the polar oxyanion hole in thrombin is not suitable for the accommodation of bulky substituents of low polarity, thereby confirming previous findings. In contrast, tricyclic lactam (+)-2 (Ki=9 nM, Ki(trypsin)/Ki(thrombin)=1055) and tricyclic imide (+)-21 (Ki=36 nM, Ki(trypsin)/Ki(thrombin)=50) with OH-substituents at the (R)-configured C(7)-atom are among the most-potent and most-selective thrombin inhibitors in their respective classes, prepared today. While initial modeling predicted H-bonding between the OH group at C(7) in (+)-2 and (+)-21 with the H2O molecule bound in the oxyanion hole (Fig. 2), the X-ray crystal structure of the complex of (+)-21 (Fig. 7, b) revealed a different interaction for this group. The propionate side chain of Glu192 undergoes a conformational change, thereby re-orienting towards the OH group at C(7) under formation of a very short ionic H-bond (OH⋅⋅⋅−OOC; d(O⋅⋅⋅O)=2.4 A). The energetic contribution of this H-bond, however, is negligible, due to its location on the surface of the protein and the unfavorable conformation of the H-bonded propionate side chain.

[1]  Manfred Kansy,et al.  Fluorine Interactions at the Thrombin Active Site: Protein Backbone Fragments HCαCO Comprise a Favorable CF Environment and Interactions of CF with Electrophiles , 2004, Chembiochem : a European journal of chemical biology.

[2]  F. Diederich,et al.  A fluorine scan of the phenylamidinium needle of tricyclic thrombin inhibitors: effects of fluorine substitution on pKa and binding affinity and evidence for intermolecular C-F...CN interactions. , 2004, Organic & biomolecular chemistry.

[3]  G. Gilliland,et al.  Crystal structure of the complex between thrombin and the central "E" region of fibrin. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[4]  F. Diederich,et al.  Medicinal chemistry in academia: molecular recognition with biological receptors. , 2004, Chemical communications.

[5]  D. Musil,et al.  Synthesis and SAR of thrombin inhibitors incorporating a novel 4-amino-morpholinone sscaffold: analysis of X-ray crystal structure of enzyme inhibitor complex. , 2003, Journal of medicinal chemistry.

[6]  C. Park,et al.  Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide. , 2003, Journal of medicinal chemistry.

[7]  W. M. Sanders,et al.  Azaindoles: moderately basic P1 groups for enhancing the selectivity of thrombin inhibitors. , 2003, Bioorganic & medicinal chemistry letters.

[8]  Stephen Hanessian,et al.  Targeting thrombin and factor VIIa: design, synthesis, and inhibitory activity of functionally relevant indolizidinones. , 2002, Bioorganic & medicinal chemistry letters.

[9]  F. Diederich,et al.  Structure‐Based Design of Nonpeptidic Thrombin Inhibitors: Exploring the D‐Pocket and the Oxyanion Hole , 2002 .

[10]  P. Winocour,et al.  Novel bicyclic lactam inhibitors of thrombin: highly potent and selective inhibitors. , 2002, Bioorganic & medicinal chemistry letters.

[11]  H. Nar,et al.  Structure-based design of novel potent nonpeptide thrombin inhibitors. , 2002, Journal of medicinal chemistry.

[12]  J. Ho,et al.  Novel, potent non-covalent thrombin inhibitors incorporating p(3)-lactam scaffolds. , 2002, Bioorganic & medicinal chemistry letters.

[13]  J. Rubin,et al.  Novel bicyclic lactam inhibitors of thrombin: potency and selectivity optimization through P1 residues. , 2001, Bioorganic & medicinal chemistry letters.

[14]  K. Eagen,et al.  Potent, low molecular weight thrombin receptor antagonists. , 2001, Bioorganic & medicinal chemistry letters.

[15]  F. Diederich,et al.  Synthesis of Novel Nonpeptidic Thrombin Inhibitors , 2000 .

[16]  N. Culeddu,et al.  Enantiomerically pure pyridine and 2,2'-bipyridine thioethers: new N-S chiral ligands for asymmetric catalysis. Palladium catalyzed allylic alkylation , 1999 .

[17]  K. Menear.  Progress towards the discovery of orally active thrombin inhibitors. , 1998, Current medicinal chemistry.

[18]  A. Naylor-Olsen,et al.  Thrombin inhibitor design. , 1998, Current medicinal chemistry.

[19]  Hugo Kubinyi,et al.  MOLEKULARE AHNLICHKEIT. 2. STRUKTURBASIERTER ENTWURF VON WIRKSTOFFEN , 1998 .

[20]  H. C. Aspinall,et al.  An improved Williamson etherification of hindered alcohols promoted by 15-crown-5 and sodium hydride , 1997 .

[21]  D W Banner,et al.  Molecular recognition at the thrombin active site: structure-based design and synthesis of potent and selective thrombin inhibitors and the X-ray crystal structures of two thrombin-inhibitor complexes. , 1997, Chemistry & biology.

[22]  F. Diederich,et al.  Design of Novel, Nonpeptidic Thrombin Inhibitors and Structure of a Thrombin–Inhibitor Complex , 1995 .

[23]  L. Weber,et al.  DESIGN NEUARTIGER, NICHTPEPTIDISCHER THROMBIN-INHIBITOREN UND STRUKTUR EINES THROMBIN: INHIBITOR-KOMPLEXES , 1995 .

[24]  Paul R. Gerber,et al.  MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry , 1995, J. Comput. Aided Mol. Des..

[25]  K Gubernator,et al.  Design and synthesis of potent and highly selective thrombin inhibitors. , 1994, Journal of medicinal chemistry.

[26]  A. Patchett,et al.  Synthesis and structure-activity relationships of peptidyl alpha-keto heterocycles as novel inhibitors of prolyl endopeptidase. , 1994, Journal of medicinal chemistry.

[27]  Maria Cristina Burla,et al.  SIR92 – a program for automatic solution of crystal structures by direct methods , 1994 .

[28]  D. Banner,et al.  Crystallographic analysis at 3.0-A resolution of the binding to human thrombin of four active site-directed inhibitors. , 1994, The Journal of biological chemistry.

[29]  S. Ley,et al.  Substitution reactions of 2-phenylsulphonyl-piperidines and -pyrrolidines with carbon nucleophiles: Synthesis of the pyrrolidine alkaloids norruspoline and ruspolinone , 1991 .

[30]  H. Wynberg,et al.  Conformational study of cinchona alkaloids. A combined NMR and molecular orbital approach , 1990 .

[31]  W. M. Davis,et al.  Structural Characterization of the Pseudoenantiomeric cis-Dioxo Osmium(VI) Esters of Chiral Diols with Cinchona Alkaloid Ligands† , 1990 .

[32]  K. Sharpless,et al.  Strukturelle Charakterisierung pseudoenantiomerer cis‐Dioxoosmium(VI)‐Komplexe mit chiralen Diolen und Cinchona‐Alkaloid‐Liganden , 1990 .

[33]  R. Huber,et al.  The refined 1.9 A crystal structure of human alpha‐thrombin: interaction with D‐Phe‐Pro‐Arg chloromethylketone and significance of the Tyr‐Pro‐Pro‐Trp insertion segment. , 1989, The EMBO journal.

[34]  S. Kanemasa,et al.  Recent Advances in Azomethine Ylide Chemistry , 1989 .

[35]  B. Furie,et al.  The molecular basis of blood coagulation , 1988, Cell.

[36]  R. Grigg,et al.  The decarboxylative route to azomethine ylides. Mechanism of 1,3-dipole formation , 1987 .

[37]  J. Hall,et al.  The action of thrombin on peptide p-nitroanilide substrates. Substrate selectivity and examination of hydrolysis under different reaction conditions. , 1983, Biochimica et biophysica acta.

[38]  R. Huisgen.  1,3-Dipolar cycloadditions. 76. Concerted nature of 1,3-dipolar cycloadditions and the question of diradical intermediates , 1976 .

[39]  A. Pinner,et al.  Umwandlung der Nitrile in Imide , 1878 .